 TEL AVIV, Israel and SEATTLE, June 23, 2021 PRNewswire -- Chemomab Therapeutics, Ltd. NASDAQ: CMMB, a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization CDMO, today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA NASH. 